Company / Shareholders' Equity
Vaxcyte, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$2.7B
FY2025
5-year range
$284.0M / $3.3B
FY2021-FY2025
Trend
-18.8%
vs FY2024
Sector context
#25 of 213
Health Care
What the data says
Vaxcyte, Inc.'s shareholders' equity of $2.7B is higher than 88% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 8 years, ranging from -$106M in FY2019 to $3.3B in FY2024.
Based on SEC 10-K filings.
$2.7B in FY2025 with a 5-year CAGR of +50.7%. Top quartile in the Health Care sector.
Improved from $1.2B to $2.7B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +41.2%
- 5-Year CAGR
- +50.7%
- 10-Year CAGR
- -
Sector benchmark
+5.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +50.7%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 18.8% year-over-year.
- Ranks #25 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.7B | -18.8% |
| FY2024 | $3.3B | +166.5% |
| FY2023 | $1.2B | +30.1% |
| FY2022 | $953.6M | +235.8% |
| FY2021 | $284.0M | -17.9% |
| FY2020 | $345.8M | +425.1% |
| FY2019 | -$106.4M | -84.3% |
| FY2018 | -$57.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026